JP2019517267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517267A5 JP2019517267A5 JP2018564239A JP2018564239A JP2019517267A5 JP 2019517267 A5 JP2019517267 A5 JP 2019517267A5 JP 2018564239 A JP2018564239 A JP 2018564239A JP 2018564239 A JP2018564239 A JP 2018564239A JP 2019517267 A5 JP2019517267 A5 JP 2019517267A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- her1t
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 230000011664 signaling Effects 0.000 claims description 35
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 239000012642 immune effector Substances 0.000 claims description 21
- 229940121354 immunomodulator Drugs 0.000 claims description 21
- 230000000139 costimulatory effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 19
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims description 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 102000001301 EGF receptor Human genes 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 108060006698 EGF receptor Proteins 0.000 claims description 10
- 240000007019 Oxalis corniculata Species 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 108010020764 Transposases Proteins 0.000 claims description 6
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 5
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101150090033 DRB2 gene Proteins 0.000 claims description 3
- 101100117568 Oryza sativa subsp. japonica DRB5 gene Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110311A JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347503P | 2016-06-08 | 2016-06-08 | |
| US62/347,503 | 2016-06-08 | ||
| PCT/US2017/036440 WO2017214333A1 (en) | 2016-06-08 | 2017-06-07 | Cd33 specific chimeric antigen receptors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110311A Division JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Division JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517267A JP2019517267A (ja) | 2019-06-24 |
| JP2019517267A5 true JP2019517267A5 (https=) | 2020-07-09 |
| JP7591342B2 JP7591342B2 (ja) | 2024-11-28 |
Family
ID=59071136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564239A Active JP7591342B2 (ja) | 2016-06-08 | 2017-06-07 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2022110311A Withdrawn JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Pending JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110311A Withdrawn JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Pending JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11787848B2 (https=) |
| EP (1) | EP3468994A1 (https=) |
| JP (3) | JP7591342B2 (https=) |
| KR (3) | KR102469703B1 (https=) |
| CN (2) | CN118652336A (https=) |
| AU (2) | AU2017279548B2 (https=) |
| CA (1) | CA3025667A1 (https=) |
| IL (2) | IL321834A (https=) |
| SG (1) | SG11201810640RA (https=) |
| WO (1) | WO2017214333A1 (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| KR102660336B1 (ko) | 2017-03-27 | 2024-04-26 | 내셔널 유니버시티 오브 싱가포르 | 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도 |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| US12053490B2 (en) * | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
| US12083192B2 (en) * | 2017-12-04 | 2024-09-10 | Actinium Pharmaceuticals, Inc. | Methods for treatment of patients with myelodysplastic syndromes |
| EP3749686A4 (en) * | 2018-02-09 | 2022-01-05 | National University of Singapore | ADHESION RECEPTOR CONSTRUCTS AND THEIR USES IN IMMUNOTHERAPY WITH NATURAL KILLER CELLS |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CN112004829A (zh) | 2018-03-12 | 2020-11-27 | 南克维斯特公司 | Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途 |
| CN111918877A (zh) * | 2018-03-14 | 2020-11-10 | 美国卫生和人力服务部 | 抗cd33嵌合抗原受体及其用途 |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| US11319380B2 (en) * | 2018-06-04 | 2022-05-03 | Precigen, Inc. | MUC16 specific chimeric antigen receptors and uses thereof |
| WO2019236647A1 (en) * | 2018-06-05 | 2019-12-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapy |
| US20210236547A1 (en) * | 2018-06-05 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid production, expansion, and increased purity of car-t cells using beads with protein l |
| CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
| CN110699318A (zh) * | 2018-07-09 | 2020-01-17 | 广西慧宝源健康产业有限公司 | T细胞培养基及培养方法 |
| EP3820484A4 (en) * | 2018-07-10 | 2022-05-04 | Precigen, Inc. | ROR-1 SPECIFIC CHIMERA ANTIGEN RECEPTORS AND USES THEREOF |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN113416251B (zh) * | 2018-09-26 | 2022-05-17 | 重庆精准生物技术有限公司 | 抗cd123人源化单链抗体及其应用 |
| US11701408B2 (en) * | 2018-10-11 | 2023-07-18 | Nantcell, Inc. | Treatment of immunosuppressed subjects |
| SG11202104524YA (en) * | 2018-11-01 | 2021-05-28 | Gracell Biotechnologies Shanghai Co Ltd | Compositions and methods for t cell engineering |
| WO2020095113A1 (en) * | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd | Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof |
| US12590148B2 (en) | 2018-11-26 | 2026-03-31 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| US12291560B2 (en) | 2018-12-14 | 2025-05-06 | Regeneron Pharmaceuticals, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| US12101761B2 (en) | 2019-01-10 | 2024-09-24 | Sony Group Corporation | Communications devices, methods of operating communications devices, infrastructure equipment and methods |
| US20230348556A1 (en) * | 2019-02-21 | 2023-11-02 | Arbele Limited | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JP7664180B2 (ja) * | 2019-04-26 | 2025-04-17 | アロジーン セラピューティクス，インコーポレイテッド | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| EP3962527A4 (en) | 2019-04-30 | 2023-11-01 | Senti Biosciences, Inc. | CHIMERIC RECEPTORS AND METHODS OF USE THEREOF |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| KR20210033436A (ko) * | 2019-09-18 | 2021-03-26 | 주식회사 에스엘바이젠 | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 |
| IL292924A (en) | 2019-11-26 | 2022-07-01 | Novartis Ag | Chimeric antigen receptors cd19 and cd22 and their uses |
| CA3165076A1 (en) | 2020-01-17 | 2021-07-22 | Ryan Clarke | Safety switches for regulation of gene expression |
| US12091681B2 (en) | 2020-03-27 | 2024-09-17 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| WO2021202799A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| CN116133679A (zh) | 2020-06-30 | 2023-05-16 | 门德斯有限公司 | 白血病衍生细胞在卵巢癌疫苗中的用途 |
| KR20230040364A (ko) * | 2020-07-27 | 2023-03-22 | 센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 | 키메라 항원 수용체 및 이의 용도 |
| WO2022052913A1 (en) * | 2020-09-08 | 2022-03-17 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for t cell engineering |
| IL302335A (en) * | 2020-10-26 | 2023-06-01 | Res Inst Nationwide Childrens Hospital | NK cells with chimeric antigen receptor (CAR) and uses thereof |
| WO2022097068A1 (en) | 2020-11-05 | 2022-05-12 | Dcprime B.V. | Use of tumor-independent antigens in immunotherapies |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| AU2022211682A1 (en) | 2021-01-22 | 2023-08-03 | Mendus B.V. | Methods of tumor vaccination |
| US20240226294A9 (en) * | 2021-02-15 | 2024-07-11 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Customized chimeric antigen receptor polypeptides |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| CN115724969A (zh) * | 2021-08-27 | 2023-03-03 | 合肥瀚科迈博生物技术有限公司 | Lag-3结合分子及其应用 |
| WO2023143209A1 (zh) * | 2022-01-25 | 2023-08-03 | 广东东阳光药业股份有限公司 | 病毒载体及其应用 |
| US20250135002A1 (en) * | 2022-02-04 | 2025-05-01 | Duke University | Compositions for and method of effecting tumor cell death |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| US20250101382A1 (en) | 2022-03-11 | 2025-03-27 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| JP2025516189A (ja) * | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| WO2024097315A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| AU2023400596A1 (en) * | 2022-11-29 | 2025-06-19 | Malcorp Biodiscoveries Limited | Novel cd20 protein |
| CN116789837B (zh) * | 2023-03-24 | 2024-02-23 | 山西纳安生物科技股份有限公司 | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 |
| JP2026512487A (ja) * | 2023-04-18 | 2026-04-16 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａキメラ抗原受容体及びその使用 |
| WO2024229302A1 (en) | 2023-05-03 | 2024-11-07 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| CN119613562A (zh) * | 2023-09-14 | 2025-03-14 | 重庆精准生物技术有限公司 | 细胞因子融合蛋白及其应用 |
| CN117587014B (zh) * | 2023-11-24 | 2025-01-24 | 上海恩凯细胞技术有限公司 | 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用 |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6007814A (en) | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| WO1994028143A1 (en) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| JP3926842B2 (ja) | 1995-03-08 | 2007-06-06 | ザ・スクリプス・リサーチ・インステイチユート | 抗原提示系およびｔ−細胞の活性化方法 |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| ATE347588T1 (de) | 1996-05-23 | 2006-12-15 | Scripps Research Inst | Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| CA2386270A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| JP5031967B2 (ja) | 2000-03-22 | 2012-09-26 | イントレキソン コーポレーション | 新規エクジソン受容体ベースの誘導性遺伝子発現系 |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| ES2424812T3 (es) | 2001-02-20 | 2013-10-08 | Intrexon Corporation | Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso |
| CA2438133C (en) | 2001-02-20 | 2015-01-27 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| WO2002066613A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system |
| EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2003027289A1 (en) | 2001-09-26 | 2003-04-03 | Rheo Gene Holdings, Inc. | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| CA2459807C (en) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| AU2003231048A1 (en) | 2002-04-22 | 2003-11-03 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| ES2579762T3 (es) | 2006-03-01 | 2016-08-16 | Janssen Pharmaceutica N.V. | Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas |
| CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
| BRPI0807952A2 (pt) | 2007-02-20 | 2014-06-10 | Anaptysbio Inc | Sistemas de hipermutação somática |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| KR101666228B1 (ko) | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| HUE035406T2 (en) | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
| US7985559B2 (en) | 2007-10-19 | 2011-07-26 | Amgen Inc. | Methods of selecting epidermal growth factor receptor (EGFR) binding agents |
| CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| CA2794196A1 (en) | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| CN103298489A (zh) | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | 新型egfr结合分子及其免疫偶联物 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| SG10201600912SA (en) | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2014159415A1 (en) | 2013-03-12 | 2014-10-02 | Bio-Rad Laboratories, Inc. | Colloidal coomassie stain |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| EA201691214A1 (ru) | 2013-12-13 | 2016-12-30 | Дженентек, Инк. | Антитела к cd33 и иммуноконъюгаты |
| US20160333108A1 (en) | 2014-01-13 | 2016-11-17 | Stephen J. Forman | CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE |
| EP3656864A1 (en) | 2014-02-14 | 2020-05-27 | Board of Regents, The University of Texas System | Chimeric antigen receptors and methods of making |
| EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| EP3126390B2 (en) * | 2014-04-03 | 2026-01-07 | Cellectis | Cd33 specific chimeric antigen receptors for cancer immunotherapy |
| CA2945320A1 (en) * | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| US11041021B2 (en) * | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| SG10201913765YA (en) | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| CN107002084B (zh) * | 2014-09-19 | 2021-09-10 | 希望之城公司 | 靶向IL13Rα2的共刺激嵌合抗原受体T细胞 |
| CA2964783C (en) * | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| AU2015343013B2 (en) | 2014-11-05 | 2020-07-16 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| ES2869972T3 (es) | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| KR102615825B1 (ko) | 2015-03-11 | 2023-12-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전위효소 폴리펩타이드 및 이의 용도 |
| JP7010473B2 (ja) * | 2015-06-04 | 2022-02-10 | ユニバーシティ オブ サザン カリフォルニア | Ｌｙｍ－１およびｌｙｍ－２標的化ｃａｒ細胞免疫療法 |
| EP4424326A3 (en) * | 2015-06-10 | 2024-11-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
-
2017
- 2017-06-07 SG SG11201810640RA patent/SG11201810640RA/en unknown
- 2017-06-07 CN CN202410513486.2A patent/CN118652336A/zh active Pending
- 2017-06-07 KR KR1020197000376A patent/KR102469703B1/ko active Active
- 2017-06-07 KR KR1020247010094A patent/KR20240111740A/ko active Pending
- 2017-06-07 IL IL321834A patent/IL321834A/en unknown
- 2017-06-07 CN CN201780048487.2A patent/CN110191898B/zh active Active
- 2017-06-07 AU AU2017279548A patent/AU2017279548B2/en active Active
- 2017-06-07 JP JP2018564239A patent/JP7591342B2/ja active Active
- 2017-06-07 EP EP17731047.1A patent/EP3468994A1/en active Pending
- 2017-06-07 CA CA3025667A patent/CA3025667A1/en active Pending
- 2017-06-07 US US15/616,869 patent/US11787848B2/en active Active
- 2017-06-07 WO PCT/US2017/036440 patent/WO2017214333A1/en not_active Ceased
- 2017-06-07 KR KR1020227040331A patent/KR102652827B1/ko active Active
- 2017-06-07 IL IL263220A patent/IL263220B2/en unknown
-
2022
- 2022-07-08 JP JP2022110311A patent/JP2022153434A/ja not_active Withdrawn
-
2023
- 2023-09-06 US US18/462,207 patent/US12559536B2/en active Active
-
2024
- 2024-06-17 JP JP2024097538A patent/JP2024138280A/ja active Pending
- 2024-07-16 AU AU2024204877A patent/AU2024204877A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517267A5 (https=) | ||
| JP2024138280A5 (https=) | ||
| US12371470B2 (en) | Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen | |
| JP2021525534A5 (https=) | ||
| AU2018207281B2 (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| JP2021530217A5 (https=) | ||
| US12590312B2 (en) | NR4A super-repressors and methods of use thereof | |
| KR20210043562A (ko) | Ror-1 특이적 키메라 항원 수용체 및 그의 용도 | |
| JP2024023232A5 (https=) | ||
| CA3093919A1 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| RS62733B1 (sr) | Mnd promoter himernih antigenskih receptora | |
| JPWO2020014366A5 (https=) | ||
| KR20210021493A (ko) | Muc16 특이적 키메라 항원 수용체 및 그의 용도 | |
| JP2019512251A (ja) | Ｐｄ−１及び４−１ｂｂの融合タンパク質 | |
| JP2020530993A (ja) | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 | |
| CN113881694A (zh) | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| JPWO2019236577A5 (https=) | ||
| US20240009235A1 (en) | T cell receptors directed against bob1 and uses thereof | |
| CN115315439A (zh) | 细胞 | |
| RU2795198C2 (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| KR20260052956A (ko) | TGFβ 스위치 수용체, 이를 코딩하는 핵산, 이를 포함하는 세포 및 약학 조성물 | |
| RU2023106937A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| AU2024310260A9 (en) | Synthetic cytokine receptors | |
| CN121693513A (zh) | TGFβ转换受体、编码它的核酸、细胞和包含它的药物组合物 |